Regeneron's Eylea Soars, But Praluent Is Slow Out Of The Gate
This article was originally published in Scrip
Regeneron Pharmaceuticals Inc. turned in a strong quarter for its ophthalmology blockbuster Eylea (aflibercept), and predicts 20% growth for the drug's fifth year on the market. But the attention-grabber out of its fourth quarter and full-year 2015 earnings report was the sluggish launch of PCSK9 inhibitor Praluent (alirocumab).
Register for our free email digests: